Fund moves

Tenax Therapeutics (TENX): Perceptive Advisors LLC added to its stake +1.01M shares

Perceptive Advisors LLC added to its stake in Tenax Therapeutics, per its Q1 2026 13F.

1.45M
Shares reported · +1.01M vs prior quarter
0.45%
Disclosed portfolio weight
$23.2M
Reported value
Holdings as of
Mar 31, 2026
Filed
May 29, 2026

What stands out in this filing

  • 439,142 shares in Q4 2025, 1,447,782 now (+229.7% in share count).
  • Reported at $23.2M, 0.45% of the portfolio value in this 13F filing.
  • No other tracked manager reported the same kind of change for Q1 2026.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 22, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On April 22, 2026, Tenax Therapeutics, Inc. (the “Company”) announced the appointment of Thomas R. Staab, II as Chief Financial Officer of the Company effective May 11, 2026 (the “Start Date”).”
  2. May 12, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Jun 26, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On June 26, 2026, the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved amendments to the employment agreements of Christopher Giordano, Thomas Staab, and Stuart Rich (collectively, the “Employment Agreement Amendments”).”
  2. Jun 29, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  3. Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 20, 2026Insider · Largest insider buy since 201010% owner purchased ~$360K of TENX shares in the open market
  5. Aug 21, 2026Insider · Largest insider buy since 201010% owner purchased ~$1.27M of TENX shares in the open market
  6. Aug 24, 2026Insider10% owner purchased ~$188K of TENX shares in the open market
  7. Aug 31, 2026Insider10% owner purchased ~$723K of TENX shares in the open market
  8. Sep 1, 2026Insider10% owner purchased ~$322K of TENX shares in the open market
  9. Sep 2, 2026Insider10% owner purchased ~$338K of TENX shares in the open market
  10. Sep 3, 2026Insider · Largest insider buy since 201010% owner purchased ~$1.6M of TENX shares in the open market
  11. Sep 11, 2026Insider · 2 peopleInsiders: 2 purchases (~$22K)
  12. Sep 15, 2026InsiderCEO purchased ~$8.8K of TENX shares in the open market
  13. Sep 16, 2026Insider · 3 insiders in a week, 2nd time since 2010Director purchased ~$102K of TENX shares in the open market
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Tenax Therapeutics

For Tenax Therapeutics, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TENX page.

How this filing works

Explore the data

Common questions

What does this filing report about Tenax Therapeutics (TENX) stock?

Perceptive Advisors LLC added to its stake in Tenax Therapeutics, per its Q1 2026 13F. Now 1.45M shares, $23.2M reported value, 0.45% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2026. Filed: May 29, 2026.

What stands out in this filing?

439,142 shares in Q4 2025, 1,447,782 now (+229.7% in share count). Reported at $23.2M, 0.45% of the portfolio value in this 13F filing. No other tracked manager reported the same kind of change for Q1 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Tenax Therapeutics recently?

For Tenax Therapeutics, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days. They are listed on the TENX page.

Does this mean TENX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Tenax Therapeutics

Everything OQRO holds on this company is on its TENX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data